ReviewFrontiers in immunology2026
Research progress of tertiary lymphoid structure in hepatocellular carcinoma: from prognostic biomarkers to new strategies for immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLS) are important ectopic immune aggregates that develop within the tumor microenvironment (TME) of hepatocellular carcinoma (HCC) and have attracted increasing attention due to their potential clinical value. Recent studies have identified TLS as key players in prognosis assessment and immunotherapy response prediction in HCC, with their maturity and spatial distribution being critical determinants of clinical outcomes. TLS can be classified into intratumoral and peritumoral types, which exhibit distinct predictive values; the clinical significance of peritumoral mature TLS remains controversial. Histopathological analysis remains the gold standard for detecting TLS structure and composition. In recent years, predictive models based on CT/MRI radiomics and machine learning have achieved promising progress in non-invasive detection. This review summarizes and analyzes the formation mechanism of TLS in HCC, emphasizes their structural characteristics, spatial distribution, clinical value, and detection methods, presents current challenges and research directions, and provides a new perspective for the diagnosis and treatment of HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.